


01-14-02

A

01/11/02



J1678 U.S. PTO

<b>CERTIFICATE UNDER 37 C.F.R. 1.10</b>		Docket No. IVD 978-2
Express Mail Label No.: EL676470283US		
Date of Deposit: January 11, 2002		
I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to: Commissioner for Patents, Box Patent Application, Washington, DC 20231		
 Signature		J1046 U.S. PTO 10/044531 01/11/02
ADDRESS TO: Commissioner for Patents		
Box Patent Application Washington, DC 20231		

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional application  
under 37 CFR 1.53(b))

**APPLICATION ELEMENTS**  
See MPEP chapter 600 concerning utility patent  
application contents.

- ☒ Fee Transmittal Form  
(Submit an original, and a duplicate for fee processing)
- ☒ Specification Total Pages   
(preferred arrangement set forth below)
  - Descriptive Title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Sequence Listing or a Table Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
- ☐ Drawing(s) (35 USC 113) Total Sheets
- ☒ Oath or Declaration/ Power of Attorney Total Sheets 
  - ☐ Newly executed (original or copy)
  - ☒ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 16 completed)
  - ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
- ☐ Application Data Sheet (See 37 CFR 1.76)

- ☐ CD-Rom or CD-R, Large Table or Computer Program  
(Appendix)
- ☐ Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - ☐ Computer Readable Form (CFR)
  - ☐ Paper copy (identical to computer copy)
  - ☐ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

- ☐ Assignment Papers (cover sheet & document(s))
- ☐ 37 CFR 3 73(b) Statement ☐ Power of Attorney
- ☐ English Translation Document (if applicable)
- ☒ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
- ☒ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
- ☐ Request and Certification under 35 U.S.C. 122(b)(2)(B)(i)
- ☒ Other: Citation of References

**16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76:**

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application no: 09/341,764

Prior Application Information: Examiner: J. Kim Group Art Unit: 1617

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 17. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label or ☒ Correspondence address Below

Michael D. Alexander  
Sanofi-Synthelabo Inc.  
9 Great Valley Parkway  
Malvern, PA 19355  
Telephone No.: (610) 889-8802  
Facsimile No.: (610) 889-8799

27546  
Respectfully submitted,  
PATENT TRADEMARK OFFICE  
  
Michael D. Alexander  
Reg. No. 36,080  
January 11, 2002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Division Under 37 C.F.R. 1.53(b)  
Application of: Maruani et al.

Prior Application Serial No.: 09/341,764

Prior Filing Date: August 19, 1999

Prior Group Art Unit: 1617

Anticipated Classification of this Application:  
Class 514 Subclass 406.000

Examiner: J. Kim

For: USE OF CENTRAL CANNABINOID  
RECEPTOR ANTAGONISTS FOR THE  
PREPARATION OF DRUGS

Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

**CERTIFICATE UNDER 37 C.F.R. 1.10**

Express Mail Label Number: EL676470283US

Date of Deposit: January 11, 2002

I hereby certify that this paper is being deposited with the  
United States Postal Service "Express Mail Post Office to  
Addressee" Service on the date indicated above and is  
addressed to: Commissioner for Patents, Box Patent  
Application, Washington, DC 20231

Signature

**FEE TRANSMITTAL FORM**

The filing fee for the above-identified has been calculated as shown below:

	Number Filed	<u>Claims as Filed</u>		Number Extra	Rate	Basic Fee
Total Claims	16	-20 =		0	X \$ 18.00 =	\$740.00
Independent Claims	2	- 3 =			X \$ 84.00 =	
Multiple dependent claims(s), if any					\$280.00 =	
Total Filing Fee:						<b>\$740.00</b>

☒ Please charge the following fees to Deposit Account No. 19-0091.

☒ Filing Fee of **\$740.00**  
☐ Assignment recordal fee of \$

Please charge any additional fees under 37 CFR 1.16 which may be required, or credit any  
overpayment, to Deposit Account No. 19-0091. A **duplicate** copy of this sheet is enclosed.

☒ This application is being filed by "Express Mail" as of the date of this letter pursuant to  
37 CFR 1.10(b).

Date: January 11, 2002

Michael D. Alexander  
Michael D. Alexander  
Reg. No. 36,080

Address:  
Patent Department  
Sanofi-Synthelabo Inc.  
9 Great Valley Parkway  
Malvern, PA 19355  
Tele: (610) 889-8802  
Fax: (610) 889-8799

Division under 37 C.F.R. 1.53(b)

Application of:

MARUANI, Jeanne and SOUBIE, Philippe

Prior Application Serial No

09/341,764

Attorney Docket No.

IVD 978-2

Title:

USE OF CANNABINOID RECEPTOR  
ANTAGONISTS FOR THE  
PREPARATION OF DRUGS

**CERTIFICATE UNDER 37 C.F.R. 1.10**

Express Mail Label No.: EL676470283US

Date of Deposit: January 11, 2002

I hereby certify that the attached English Translation is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to:

Commissioner for Patents, Box PCT, Attn: EO/US,  
Washington, DC 20231

  
Signature